Radiation Nephropathy

No Results

No Results

processing….

Radiation nephropathy is kidney injury and impairment of function caused by ionizing radiation. It may occur after irradiation of one or both kidneys, and it may result in kidney failure.

Classic radiation nephropathy occurs after bilateral, local kidney irradiation. It is a syndrome of chronic renal failure, occurring months or years after renal irradiation. ^[1] Acute radiation nephropathy develops 6-12 months after irradiation, whereas chronic radiation nephropathy develops years later. Radiation nephropathy has also been discovered to cause chronic renal failure after hematopoietic stem cell transplantation (HSCT), also called bone marrow transplantation (BMT). ^[2] In addition, the use of yttrium–90–tagged (⁹⁰ Y-tagged) somatostatin and other radionuclides for radionuclide therapy cause radiation nephropathy when they are filtered by the kidneys and reabsorbed by the renal tubule epithelium or when blood-borne exposure to the kidney cells occurs. (See Etiology, Prognosis.) ^[3]

An excess occurrence of chronic kidney disease is reported in long-term survivors of the atomic bomb explosions at Hiroshima and Nagasaki. ^[4] Total or partial body radiation exposures as might occur in an accident or a belligerent exposure may also cause renal injury.

The term nephritis was commonly used in the past; however, because radiation nephropathy is not an inflammatory condition, the term nephropathy is probably more appropriate.

Radiation nephropathy is due to cellular injury caused by ionizing radiation. All components of the kidney are affected, including the glomeruli, blood vessels, tubular epithelium, and interstitium. ^[5]

In the case of local kidney irradiation or total-body irradiation, the injury is direct. In the case of injury by radionuclide therapy, a radioisotope can injure the kidneys if its pharmacokinetics cause it to lodge in the kidney during a time when it is still a radioemitter. This is the case for the⁹⁰ Y-tagged somatostatin, which has been used for the treatment of neuroendocrine malignancies, and for holmium-166–tagged (¹⁶⁶ Ho-tagged) phosphonate 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid (DOTMP). ^{[6, 7]}

Not all patients exposed to sufficient renal irradiation develop renal injury. The reason for this clinical variability is unknown. Indeed, the heterogeneity of response of healthy tissue to ionizing radiation is poorly understood. No reliable clinical predictors are available for the development of radiation nephropathy. Some individuals may develop radiation nephropathy at a dose of radiation that has no clinical effect on others.

Oxidative injury to the deoxyribonucleic acid (DNA) initiates injury to healthy tissue by ionizing radiation. This is a genotoxic injury. A cell with sufficient DNA injury eventually dies after several divisions. The delay in cell death may partially explain why radiation injury to healthy tissue is a delayed reaction.

The detailed mechanism whereby the kidney cells and tissues malfunction after this injury remains poorly understood. In experimental models, ultrastructural damage to the glomerular endothelium is observed 3 weeks after a 10 Gy (1000 rad) dose of local kidney irradiation, and neutrophil adherence to the endothelium occurs. ^[5] By 6 to10 weeks after the same dose, a wave of tubular epithelial cell deaths occur. This is followed by interstitial scarring. The scarring tends to be most severe in the outer cortex, and it proceeds inward. The progression of these events is accelerated with higher doses of radiation.

The earliest functional evidence of experimental radiation nephropathy is proteinuria, which is evident by 6 weeks in a radiation nephropathy model with 17-Gy multifraction total-body irradiation. Azotemia and hypertension are present by 12-15 weeks in the same model. The origin of the hypertension probably is similar to that of most experimental hypertension, although pressure-natriuresis curves have not been studied. Renin levels in systemic blood are normal or low, and blood and intrarenal angiotensin II levels are within the reference range (ie, not elevated).

In clinical experience, radiation nephropathy does not occur until months after the kidneys are exposed to sufficient ionizing radiation. Early data suggested that a dose of 20 Gy (2000 rads) given in multiple fractions over several weeks can cause radiation nephropathy. ^[1] Ten-Gy single-fraction total body irradiation (TBI) causes chronic renal failure after irradiation within 6-12 months after TBI. The long-term Hiroshima-Nagasaki data suggest that a single fraction dose as low as 1 Gy is associated with an elevated risk of chronic kidney disease over many years of follow-up.

Radiation nephropathy after BMT (BMT nephropathy) occurs following a lower dose of radiation than had been traditionally accepted. This dose is given over days, not weeks, to the whole body (total-body irradiation) and is accompanied by chemotherapy, which may account for the unexpectedly dramatic effect on the kidneys. Proteinuria is usual, although generally not in the nephrotic range. Azotemia and hypertension also develop. Anemia out of proportion to the degree of azotemia is a characteristic finding.

Severe cases of radiation nephropathy after BMT may be associated with a picture that appears similar to the hemolytic uremic syndrome (HUS), with thrombocytopenia, microangiopathic hemolytic anemia, and a high blood level of lactate dehydrogenase (LDH). This last syndrome may be the result of severe endothelial injury.

In the case of unilateral renal irradiation, progressive scarring of the irradiated kidney may occur, with severe hypertension related to renin release by the single irradiated kidney.

Clinical radiation nephropathy, and its congener, the BMT nephropathy syndrome, have been reported worldwide.

Radiation nephropathy does not occur in all irradiated patients. In the large British series of classic radiation nephropathy described by Luxton, only 20% of subjects developed radiation nephropathy, although each received more than 2500 rads to the kidneys. ^[1] The form of radiation nephropathy in patients who receive BMT occurs in 10-20% of these patients.

In a report from Seattle, Wash, 30 of 83 subjects treated with ¹⁶⁶ Ho tagged DOTMP developed some kidney injury; 7 subjects had thrombotic microangiopathy (ie, hemolytic-uremic syndrome [HUS]). ^[7]

No confirmed sex-based differences in radiation nephropathy have been reported. At the BMT unit of the Medical College of Wisconsin, BMT nephropathy has affected more women than men, but other centers have not had this experience. No age-based differences in susceptibility to classic radiation nephropathy have been confirmed. However, in the case of BMT nephropathy, children appear to be more likely to develop this syndrome than adults.

No racial or ethnic predisposition to radiation nephropathy has been identified.

Radiation nephropathy may progress to end-stage renal failure. The same is true of BMT nephropathy; the occurrence of end-stage renal failure in subjects who have undergone BMT is almost 20 times higher than it is in the age-matched general population. ^[8] The progression to end-stage renal failure has also occurred after internal radioisotope radiotherapy. Complete renal failure may evolve in weeks in severe cases, and after years in less severe cases. One can predict when a patient will need dialysis by making a graph of 100/plasma creatinine versus time. At the point where the 100/plasma creatinine value is equal to 10, the estimated renal function is approximately 10% of normal, revealing that dialysis may be needed soon after that. (See Rate of Kidney Function Loss.)

Patients with BMT nephropathy whose renal function declines to the point of their needing chronic dialysis have a poor prognosis compared with that of age-matched control subjects receiving dialysis. This probably is related to the burden of immunosuppression and past illness associated with BMT. Individuals with BMT nephropathy may also have accelerated atherosclerosis, which may be related to total-body irradiation and chemotherapy. ^[9]

As with other causes of chronic renal failure, radiation nephropathy may be asymptomatic. When it sufficiently reduces kidney function, symptoms and signs of renal failure occur. End-stage renal disease and the need for dialysis or transplantation may develop. In patients with BMT nephropathy who are receiving dialysis, the survival rate is less than that of age-matched control subjects. ^[10]

Proteinuria occurs, but it is usually not a striking feature in patients with radiation nephropathy. Reports of classic radiation nephropathy generally describe non–nephrotic-range proteinuria (< 3 g/d). In BMT nephropathy, the average urinary protein level has been reported at 2.5 g/d. Fluid overload, edema, pulmonary edema, and hyperkalemia are additional complications that can occur in these patients.

In classic radiation nephropathy, malignant hypertension may affect as many as 30% of patients and can occur as late as 11 years after irradiation. In BMT nephropathy, hypertension is a cardinal feature and observed along with azotemia. Were it not for antihypertensive agents, malignant hypertension would probably be a major feature of BMT nephropathy.

On hematologic analysis, accompanying anemia is present in radiation nephropathy and BMT nephropathy and is more severe than that expected for the degree of azotemia. In severe cases of BMT nephropathy, hemolytic anemia, a high blood LDH level, and a decreased platelet count may be present. This syndrome may be mistaken for HUS or thrombotic thrombocytopenic purpura (TTP).

Luxton RW. Radiation nephritis. A long-term study of 54 patients. Lancet. 1961 Dec 2. 2:1221-4. [Medline].

Cohen EP. Radiation nephropathy after bone marrow transplantation. Kidney Int. 2000 Aug. 58(2):903-18. [Medline].

Cohen EP, Moulder JE, Robbins ME. Radiation nephropathy caused by yttrium 90. Lancet. 2001 Sep 29. 358(9287):1102-3. [Medline].

Sera N, Hida A, Imaizumi M, Nakashima E, Akahoshi M. The association between chronic kidney disease and cardiovascular disease risk factors in atomic bomb survivors. Radiat Res. 2013 Jan. 179(1):46-52. [Medline].

Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol. 2003 Sep. 23(5):486-99. [Medline].

Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001 Apr. 37(4):847-51. [Medline].

Giralt S, Bensinger W, Goodman M, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood. 2003 Oct 1. 102(7):2684-91. [Medline].

Cohen EP, Drobyski WR, Moulder JE. Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 May. 39(9):571-2. [Medline].

Akasheh M, Priyanath A, Pello N, et al. Accelerated atherosclerosis in a patient with post-BMT nephropathy. Bone Marrow Transplant. 1999 Jan. 23(2):199. [Medline].

Cohen EP, Piering WF, Kabler-Babbitt C, Moulder JE. End-stage renal disease (ESRD) after bone marrow transplantation: poor survival compared to other causes of ESRD. Nephron. 1998 Aug. 79(4):408-12. [Medline].

Antignac C, Gubler MC, Leverger G, Broyer M, Habib R. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int. 1989 Jun. 35(6):1336-44. [Medline].

Bernauer W, Gratwohl A, Keller A, Daicker B. Microvasculopathy in the ocular fundus after bone marrow transplantation. Ann Intern Med. 1991 Dec 15. 115(12):925-30. [Medline].

Cohen EP, Pais P, Moulder JE. Chronic kidney disease after hematopoietic stem cell transplantation. Semin Nephrol. 2010 Nov. 30(6):627-34. [Medline]. [Full Text].

Stevens LA, Coresh J, Greene T, et al. Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med. 2006 Jun 8. 354(23):2473-83. [Medline].

Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001 Jun. 12(6):1164-72. [Medline].

Choi HJ, Shim H, Hyun H, Gerbaudo VH, Kim CK. FDG PET/CT Appearance of Radiation Nephritis. Clin Nucl Med. 2015 Nov 11. [Medline].

Keane WF, Crosson JT, Staley NA, et al. Radiation-induced renal disease. A clinicopathologic study. Am J Med. 1976 Jan. 60(1):127-37. [Medline].

Choi KL, Bakris GL. Hypertension treatment guidelines: practical implications. Semin Nephrol. 2005 Jul. 25(4):198-209. [Medline].

Cohen EP, Hussain S, Moulder JE. Successful treatment of radiation nephropathy with angiotensin II blockade. Int J Radiat Oncol Biol Phys. 2003 Jan 1. 55(1):190-3. [Medline].

Moulder JE, Fish BL, Cohen EP. Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Radiother Oncol. 1998 Mar. 46(3):307-15. [Medline].

Cohen EP, Irving AA, Drobyski WR, et al. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2008 Apr 1. 70(5):1546-51. [Medline].

Sarode R, McFarland JG, Flomenberg N, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1995 Aug. 16(2):271-5. [Medline].

Eric P Cohen, MD Professor, Department of Medicine, Division of Nephrology, University of Maryland School of Medicine; Nephrology Section Chief, Baltimore Veterans Affairs Hospital

Eric P Cohen, MD is a member of the following medical societies: American Society of Nephrology, International Society of Nephrology, Radiation Research Society, Société Francophone de Dialyse

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ajay K Singh, MB, MRCP, MBA Associate Professor of Medicine, Harvard Medical School; Director of Dialysis, Renal Division, Brigham and Women’s Hospital; Director, Brigham/Falkner Dialysis Unit, Faulkner Hospital

Disclosure: Nothing to disclose.

Vecihi Batuman, MD, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Laura Lyngby Mulloy, DO, FACP Professor of Medicine, Chief, Section of Nephrology, Hypertension, and Transplantation Medicine, Glover/Mealing Eminent Scholar Chair in Immunology, Medical College of Georgia, Georgia Regents University

Disclosure: Nothing to disclose.

Radiation Nephropathy

Research & References of Radiation Nephropathy|A&C Accounting And Tax Services
Source

Share on Facebook

Tweet

Follow us